{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:11:21Z","timestamp":1782537081592,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1168194"],"award-info":[{"award-number":["APP1168194"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["Centre for Research Excellence in Melanoma grant, APP1135285"],"award-info":[{"award-number":["Centre for Research Excellence in Melanoma grant, APP1135285"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["Investigator Grant (APP1194703)"],"award-info":[{"award-number":["Investigator Grant (APP1194703)"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014467","name":"Western Sydney Local Health District","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014467","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["Fellowship"],"award-info":[{"award-number":["Fellowship"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40271-021-00507-1","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T02:02:15Z","timestamp":1616551335000},"page":"635-647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6836-0382","authenticated-orcid":false,"given":"Ann","family":"Livingstone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4945-0857","authenticated-orcid":false,"given":"Kathy","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6106-6298","authenticated-orcid":false,"given":"Danielle Marie","family":"Muscat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5183-7562","authenticated-orcid":false,"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3793-8724","authenticated-orcid":false,"given":"Martin R.","family":"Stockler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-0572","authenticated-orcid":false,"given":"Rachael L.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"507_CR1","unstructured":"Skin Cancer Foundation. Melanoma overview: a dangerous cancer. 2020. https:\/\/www.skincancer.org\/skin-cancer-information\/melanoma\/. Accessed 24 July 2020."},{"issue":"6","key":"507_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin."},{"issue":"19","key":"507_CR3","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845\u201355.","journal-title":"N Engl J Med."},{"issue":"19","key":"507_CR4","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801.","journal-title":"N Engl J Med."},{"issue":"19","key":"507_CR5","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335.","journal-title":"N Engl J Med."},{"issue":"6","key":"507_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin. 2017;67(6):472\u201392.","journal-title":"CA Cancer J Clin."},{"issue":"2","key":"507_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1245\/s10434-019-07963-y","volume":"27","author":"A Livingstone","year":"2020","unstructured":"Livingstone A, Agarwal A, Stockler MR, Menzies AM, Howard K, Morton RL. Preferences for immunotherapy in melanoma: a systematic review. Ann Surg Oncol. 2020;27(2):571\u201384.","journal-title":"Ann Surg Oncol."},{"key":"507_CR8","volume-title":"Qualitative research methods","author":"M Hennink","year":"2020","unstructured":"Hennink M, Hutter I, Bailey A. Qualitative research methods. London: Sage Publishing; 2020."},{"key":"507_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/1041-6080(95)90031-4","volume":"7","author":"VF Reyna","year":"1995","unstructured":"Reyna VF, Brainerd CJ. Fuzzy-trace theory: an interim synthesis. Learn Indiv Diff. 1995;7:1\u201375.","journal-title":"Learn Indiv Diff."},{"issue":"2","key":"507_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.0963-7214.2004.00275.x","volume":"13","author":"VF Reyna","year":"2004","unstructured":"Reyna VF. How people make decisions that involve risk: a dual-processes approach. Curr Direct Psychol Sci. 2004;13(2):60\u20136.","journal-title":"Curr Direct Psychol Sci."},{"issue":"9","key":"507_CR11","first-page":"1408","volume":"20","author":"PI Fusch","year":"2015","unstructured":"Fusch PI, Ness LR. Are we there yet? Data saturation in qualitative research. Qual Rep. 2015;20(9):1408\u201316.","journal-title":"Qual Rep."},{"key":"507_CR12","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa","volume-title":"Using thematic analysis in psychology","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. London: Routledge; 2006."},{"key":"507_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4324\/9780203413081_chapter_9","volume-title":"Analysing qualitative data","author":"J Ritchie","year":"1994","unstructured":"Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In: Bryman A, Burgess RG, editors. Analysing qualitative data. London: Routledge; 1994. p. 173\u201394."},{"key":"507_CR14","doi-asserted-by":"crossref","DOI":"10.4135\/9781483398655","volume-title":"100 questions (and answers) about qualitative research","author":"LM Given","year":"2016","unstructured":"Given LM. 100 questions (and answers) about qualitative research. Thousand Oaks: Sage Publishing; 2016."},{"issue":"9","key":"507_CR15","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","volume":"89","author":"BC O'Brien","year":"2014","unstructured":"O\u2019Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245\u201351.","journal-title":"Acad Med."},{"key":"507_CR16","volume-title":"Qualitative inquiry and research design: choosing among five approaches","author":"JW Creswell","year":"2018","unstructured":"Creswell JW, Poth CN. Qualitative inquiry and research design: choosing among five approaches. 4th ed. Thousand Oaks: Sage Publications; 2018.","edition":"4"},{"issue":"8","key":"507_CR17","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1177\/1049732309341728","volume":"19","author":"E Kenne Sarenmalm","year":"2009","unstructured":"Kenne Sarenmalm E, Thoren-Jonsson AL, Gaston-Johansson F, Ohlen J. Making sense of living under the shadow of death: adjusting to a recurrent breast cancer illness. Qual Health Res. 2009;19(8):1116\u201330.","journal-title":"Qual Health Res."},{"issue":"11","key":"507_CR18","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1002\/pon.4783","volume":"27","author":"L Sharpe","year":"2018","unstructured":"Sharpe L, Curran L, Butow P, Thewes B. Fear of cancer recurrence and death anxiety. Psychooncology. 2018;27(11):2559\u201365.","journal-title":"Psychooncology."},{"issue":"Suppl. 4","key":"507_CR19","first-page":"148","volume":"13","author":"A Wong","year":"2017","unstructured":"Wong A, Billett A, McArthur G, Milne D. Understanding real-world patients\u2019 experience on pembrolizumab, anti-programmed death 1 monoclonal antibody (anti-PD-1), for advanced melanoma: a qualitative study. Asia Pac J Clin Oncol. 2017;13(Suppl. 4):148.","journal-title":"Asia Pac J Clin Oncol."},{"issue":"10","key":"507_CR20","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1177\/0269216320916154","volume":"34","author":"JA Fox","year":"2020","unstructured":"Fox JA, Rosenberg J, Ekberg S, Langbecker D. Palliative care in the context of immune and targeted therapies: a qualitative study of bereaved carers\u2019 experiences in metastatic melanoma. Palliat Med. 2020;34(10):1351\u201360.","journal-title":"Palliat Med."},{"issue":"5","key":"507_CR21","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1215\/03616878-26-5-1031","volume":"26","author":"D Haas-Wilson","year":"2001","unstructured":"Haas-Wilson D. Arrow and the information market failure in health care: the changing content and sources of health care information. J Health Polit Policy Law. 2001;26(5):1031\u201344.","journal-title":"J Health Polit Policy Law."},{"issue":"5","key":"507_CR22","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00520-018-4443-3","volume":"27","author":"D Levy","year":"2019","unstructured":"Levy D, Dhillon HM, Lomax A, Marthick M, McNeil C, Kao S, et al. Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. Support Care Cancer. 2019;27(5):1845\u201352.","journal-title":"Support Care Cancer."},{"key":"507_CR23","unstructured":"Australian Government. Pharmaceutical benefits scheme: nivolumab. 2020. https:\/\/www.pbs.gov.au\/medicine\/item\/10745M-10748Q-10764M-10775D-11143L-11150W-11152Y-11153B-11157F-11158G-11159H-11160J-11411N-11425H-11434T-11435W-11532Y-11543M-11626X-11627Y-11631E-11635J-11636K-11642R-11900H-11906P. Accessed 20 Aug 2020."},{"key":"507_CR24","unstructured":"Australian Government. Pharmaceutical benefits scheme: pembrolizumab. 2020. https:\/\/www.pbs.gov.au\/medicine\/item\/10424P-10436G-10475H-10493G-11330H-11352L-11492W-11494Y-11632F-11646Y-12119W-12120X-12121Y-12122B-12123C-12124D-12125E-12126F-12127G-12128H-12129J-12130K. Accessed 10 Sep 2020."},{"issue":"3","key":"507_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40271-016-0204-x","volume":"10","author":"LG Gordon","year":"2017","unstructured":"Gordon LG, Merollini KMD, Lowe A, Chan RJ. A systematic review of financial toxicity among cancer survivors: we can\u2019t pay the co-pay. Patient. 2017;10(3):295\u2013309.","journal-title":"Patient."},{"key":"507_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/JMDH.S104807","volume":"9","author":"A Althubaiti","year":"2016","unstructured":"Althubaiti A. Information bias in health research: definition, pitfalls, and adjustment methods. J Multidiscip Healthc. 2016;9:211\u20137.","journal-title":"J Multidiscip Healthc."},{"key":"507_CR27","doi-asserted-by":"crossref","DOI":"10.1515\/9781503620766","volume-title":"A theory of cognitive dissonance","author":"L Festinger","year":"1957","unstructured":"Festinger L. A theory of cognitive dissonance. Evanston: Row, Peterson; 1957."}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-021-00507-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-021-00507-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-021-00507-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T21:08:48Z","timestamp":1698095328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-021-00507-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["507"],"URL":"https:\/\/doi.org\/10.1007\/s40271-021-00507-1","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,24]]},"assertion":[{"value":"28 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The following postgraduate scholarships support Ann Livingstone: Australian National Health and Medical Research Council (NHMRC) APP1168194, Sydney Catalyst and Melanoma Institute Australia (MIA). The Australian NHMRC Centre of Research Excellence in Melanoma grant APP1135285 supports Kathy Dempsey. A Western Sydney Local Health District Fellowship supports Danielle Marie Muscat. A Cancer Institute New South Wales Fellowship and the MIA support Alexander M. Menzies. An Australian NHMRC Investigator Grant, APP1194703 and a University of Sydney Robinson Fellowship support Rachael L. Morton.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ann Livingstone, Kathy Dempsey, Danielle Marie Muscat, Kirsten Howard and Rachael L. Morton have no conflicts of interest that are directly relevant to the content of this article. Donna Milne served on advisory boards for BMS, MSD and Novartis, and received BMS and Merck competitive research funding. Martin R. Stockler received institutional research support from Amgen, Astellas, AstraZeneca, Bayer, Bionomics, BMS, Celgene, Medivation, MSD, Pfizer, Roche, Sanofi and Tilray, but does not sit on any advisory boards. Alexander M. Menzies served on advisory boards for BMS, MSD, Novartis, Roche, Pierre-Fabre and Qbiotics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Sydney Local Health District Human Research Ethics Committee (HREC\/18\/RPAH\/736) granted ethics approval. The Declaration of Helsinki underpinned this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written consent to participate in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"De-identified datasets used and analysed during the current study may be available from the corresponding author if the request falls within the project\u2019s ethics approval.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"AL: Conceptualisation, methodology, resources, writing\/original draft preparation; DM and AMM: supervision, assistance with participant recruitment, writing, critical review\/editing; KD: qualitative coding and analysis, writing, critical review\/editing; DMM: assistance with focus groups, writing, critical review\/editing; MRS and KH: supervision, writing, critical review\/editing; RLM: conceptualisation, supervision, assistance with focus groups, resources, writing, critical review\/editing.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"All authors have reviewed and approved the manuscript and consented to its publication.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The code used for analyses can be made available upon request for non-commercial use.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}